Solving the High cost of monoclonal antibody production.
The high cost of monoclonal antibody production makes these blockbuster drugs expensive, limiting access to large patient populations in developing and industrialized countries. The reason for high production costs is, in part, due to the use of mammalian expression systems for antibody manufacturing. While these platforms enable human-like glycosylation, which is necessary for the stability and function of antibodies, there are many disadvantages to their widespread use: Cell growth and antibody expression require expensive serum, equipment, and downstream quality control. In addition, glycosylation patterns are sensitive to mild perturbations in culturing conditions, which can reduce the quality and yield of antibody production.
To solve these problems, we’ve developed Conamax, a robust, rapid, and inexpensive microbial antibody production platform for antibody developers and the global patient populations they serve.